Novartis | NOVN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 6.88B 156M 2026-09
Alcon AG USD 44M 253M 2026-06
Almirall EUR 71.55M 41.32M 2026-06
Amgen USD 4.68B 65M 2026-09
AstraZeneca USD 4.66B 1.5B 2026-09
Autolus Therapeutics Ltd USD -59.51M 12.95M 2026-03
Bayer EUR 129M 698M 2026-09
Biogen USD 419.5M 663.3M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Eli Lilly USD 12.46B 2.68B 2026-06
Fresenius EUR 639M 80M 2026-09
Fresenius Medical Care EUR 384M 153.27M 2026-09
Genmab DKK 407M 182M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.86B 251M 2026-09
GRIFOLS EUR 394M 65M 2026-09
Hikma Pharmaceutical USD 348M 161M 2025-12
J&J USD 6.47B 1B 2026-09
Lakefront Biotherapeutics EUR -43.51M 20.19M 2026-06
Lonza CHF 673M 243M 2025-06
Merck EUR 1.1B 51M 2026-06
Merck USD 7.33B 6.49B 2026-09
Novartis USD 5.14B 392M 2026-09
Novartis USD 1.84B 2.39B 2026-09
Novo Nordisk DKK 33.76B 25.86B 2026-06
Orion EUR 209.9M 33.3M 2026-09
Pfizer USD 662M 5M 2026-09
Philips EUR 165M 445M 2026-09
Recordati EUR 203.76M 27.35M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 4.72B 2.34B 2026-09
UCB EUR 1.29B 571M 2025-12